Alan Brennan researcher
Brennan, Alan
VIAF ID: 214787448 (Personal)
Permalink: http://viaf.org/viaf/214787448
Preferred Forms
- 100 0 _ ‡a Alan Brennan ‡c researcher
- 100 1 _ ‡a Brennan, Alan
-
- 100 1 _ ‡a Brennan, Alan
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models | |
Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany | |
Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes | |
Can we use routine data to evaluate organizational change? Lessons from the evaluation of business process re-engineering in a UK teaching hospital | |
Commentary on Apostolopoulos et al. (2018): Systems and complex systems approaches for public health planning-back to the future? | |
Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials" | |
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza | |
The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation | |
The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture | |
The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. | |
The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries | |
The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model | |
The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies | |
A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK | |
A critique and impact analysis of decision modeling assumptions | |
Decision modeling to inform decision making: seeing the wood for the trees. | |
Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. | |
Does an intensive self-management structured education course improve outcomes for children and young people with type 1 diabetes? The Kids In Control OF Food (KICk-OFF) cluster-randomised controlled trial protocol | |
The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons | |
Efficient computation of partial expected value of sample information using Bayesian approximation, 2005: | |
Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model | |
Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis | |
Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method | |
Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule | |
Estimation of own and cross price elasticities of alcohol demand in the UK--A pseudo-panel approach using the Living Costs and Food Survey 2001-2009. | |
Estimation of usual occasion-based individual drinking patterns using diary survey data | |
Evaluation of the impact of a technology appraisal process in England: the South and West Development and Evaluation Committee. | |
Evolutionary parameter estimation for a theory of planned behaviour microsimulation of alcohol consumption dynamics in an English birth cohort 2003 to 2010 | |
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness | |
The impact of spatial and temporal availability of alcohol on its consumption and related harms: a critical review in the context of UK licensing policies | |
Incorporation of uncertainty in health economic modelling studies | |
Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community | |
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort | |
Introducing CASCADEPOP: an open-source sociodemographic simulation platform for US health policy appraisal | |
Is it feasible to plan secondary care services for coronary heart disease rationally? A quantified modelling approach for a UK Health Authority | |
Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4 | |
Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme | |
Modelling the Cost-Effectiveness of Alcohol Screening and Brief Interventions in Primary Care in England | |
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. | |
Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods | |
Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK | |
NHS Diabetes Prevention Programme in England: formative evaluation of the programme in early phase implementation. | |
The NICE reappraisal of biologics in 2005: what rheumatologists need to know | |
Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation | |
An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists | |
A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis | |
Policy options for alcohol price regulation: the importance of modelling population heterogeneity | |
Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study | |
Propensity score matching for selection of local areas as controls for evaluation of effects of alcohol policies in case series and quasi case-control designs. | |
Protocol for a national monthly survey of alcohol use in England with 6-month follow-up: 'the Alcohol Toolkit Study'. | |
Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense? | |
Reporting the characteristics of the policy context for population-level alcohol interventions: a proposed 'Transparent Reporting of Alcohol Intervention ContExts' (TRAICE) checklist | |
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation | |
The role of modelling in prioritising and planning clinical trials | |
THE SHEFFIELD ALCOHOL POLICY MODEL - A MATHEMATICAL DESCRIPTION. | |
The Sheffield rheumatoid arthritis health economic model | |
Should patients have a greater role in valuing health states? | |
Simulation sample sizes for Monte Carlo partial EVPI calculations. | |
The SIPHER Consortium: Introducing the new UK hub for systems science in public health and health economic research | |
Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes | |
Systematic review and meta-analysis of randomized controlled trials of psychological interventions to improve glycaemic control in children and adults with type 1 diabetes | |
Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom | |
A taxonomy of model structures for economic evaluation of health technologies. | |
Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs | |
The temporal relationship between per capita alcohol consumption and harm: a systematic review of time lag specifications in aggregate time series analyses | |
Trend analysis and modelling of gender-specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in Great Britain using the General Lifestyle Survey 1984-2009. | |
Triaging patients with serious head injury: results of a simulation evaluating strategies to bypass hospitals without neurosurgical facilities. | |
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis | |
Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. | |
Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing. | |
Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework |